Drugs / TVAX-008
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT07204236 | Jan 2024 → Mar 2025 overdue | chronic hepatitis B virus infection | Grand Theravac Life Sciences (Nanjing) Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07179653 | Jan → Dec 2025 overdue | hepatitis B virus infection | Grand Theravac Life Sciences (Nanjing) Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT07190742 | Jun 2023 → Oct 2024 overdue | chronic hepatitis B virus infection | Grand Theravac Life Sciences (Nanjing) Co., Ltd. | Active not recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TVAX-008 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07179653 ↗ |